Literature DB >> 29555627

Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.

Suzanne Scheele1, Jennifer A Geiger1, Amy E DeRocher1, Ryan Choi2, Tess R Smith2, Matthew A Hulverson2, Rama Subba Rao Vidadala3, Lynn K Barrett2, Dustin J Maly3, Ethan A Merritt4, Kayode K Ojo2, Wesley C Van Voorhis2,5, Marilyn Parsons6,5.   

Abstract

In Toxoplasma gondii, calcium-dependent protein kinase 1 (CDPK1) is an essential protein kinase required for invasion of host cells. We have developed several hundred CDPK1 inhibitors, many of which block invasion. Inhibitors with similar 50% inhibitory concentrations (IC50s) were tested in thermal shift assays for their ability to stabilize CDPK1 in cell lysates, in intact cells, or in purified form. Compounds that inhibited parasite growth stabilized CDPK1 in all assays. In contrast, two compounds that showed poor growth inhibition stabilized CDPK1 in lysates but not in cells. Thus, cellular exclusion could explain exceptions in the correlation between the action on the target and cellular activity. We used thermal shift assays to examine CDPK1 in two clones that were independently selected by growth in the CDPK1 inhibitor RM-1-132 and that had increased 50% effective concentrations (EC50s) for the compound. The A and C clones had distinct point mutations in the CDPK1 kinase domain, H201Q and L96P, respectively, residues that lie near one another in the inactive isoform. Purified mutant proteins showed RM-1-132 IC50s and thermal shifts similar to those shown by wild-type CDPK1. Reduced inhibitor stabilization (and a presumed reduced interaction) was observed only in cellular thermal shift assays. This highlights the utility of cellular thermal shift assays in demonstrating that resistance involves reduced on-target engagement (even if biochemical assays suggest otherwise). Indeed, similar EC50s were observed upon overexpression of the mutant proteins, as in the corresponding drug-selected parasites, although high levels of CDPK1(H201Q) only modestly increased resistance compared to that achieved with high levels of wild-type enzyme.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Toxoplasma gondii; bumped kinase inhibitor; cellular thermal shift assay; inhibitor; protein kinase

Mesh:

Substances:

Year:  2018        PMID: 29555627      PMCID: PMC5971589          DOI: 10.1128/AAC.00051-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.

Authors:  Daniel Martinez Molina; Rozbeh Jafari; Marina Ignatushchenko; Takahiro Seki; E Andreas Larsson; Chen Dan; Lekshmy Sreekumar; Yihai Cao; Pär Nordlund
Journal:  Science       Date:  2013-07-05       Impact factor: 47.728

Review 2.  Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.

Authors:  Wesley C Van Voorhis; J Stone Doggett; Marilyn Parsons; Matthew A Hulverson; Ryan Choi; Samuel L M Arnold; Michael W Riggs; Andrew Hemphill; Daniel K Howe; Robert H Mealey; Audrey O T Lau; Ethan A Merritt; Dustin J Maly; Erkang Fan; Kayode K Ojo
Journal:  Exp Parasitol       Date:  2017-01-05       Impact factor: 2.011

3.  The cellular thermal shift assay for evaluating drug target interactions in cells.

Authors:  Rozbeh Jafari; Helena Almqvist; Hanna Axelsson; Marina Ignatushchenko; Thomas Lundbäck; Pär Nordlund; Daniel Martinez Molina
Journal:  Nat Protoc       Date:  2014-08-07       Impact factor: 13.491

4.  Toxoplasmosis.

Authors:  Sandra K Halonen; Louis M Weiss
Journal:  Handb Clin Neurol       Date:  2013

5.  Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii.

Authors:  Ryan C Murphy; Kayode K Ojo; Eric T Larson; Alejandro Castellanos-Gonzalez; B Gayani K Perera; Katelyn R Keyloun; Jessica E Kim; Janhavi G Bhandari; Natascha R Muller; Christophe L M J Verlinde; A Clinton White; Ethan A Merritt; Wesley C Van Voorhis; Dustin J Maly
Journal:  ACS Med Chem Lett       Date:  2010-10-14       Impact factor: 4.345

6.  Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.

Authors:  Florentine U Rutaganira; Jennifer Barks; Mary Savari Dhason; Qiuling Wang; Michael S Lopez; Shaojun Long; Joshua B Radke; Nathaniel G Jones; Amarendar R Maddirala; James W Janetka; Majida El Bakkouri; Raymond Hui; Kevan M Shokat; L David Sibley
Journal:  J Med Chem       Date:  2017-10-09       Impact factor: 7.446

7.  Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.

Authors:  Steven M Johnson; Ryan C Murphy; Jennifer A Geiger; Amy E DeRocher; Zhongsheng Zhang; Kayode K Ojo; Eric T Larson; B Gayani K Perera; Edward J Dale; Panqing He; Molly C Reid; Anna M W Fox; Natascha R Mueller; Ethan A Merritt; Erkang Fan; Marilyn Parsons; Wesley C Van Voorhis; Dustin J Maly
Journal:  J Med Chem       Date:  2012-02-27       Impact factor: 7.446

8.  Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.

Authors:  Sebastian Lourido; Chao Zhang; Michael S Lopez; Keliang Tang; Jennifer Barks; Qiuling Wang; Scott A Wildman; Kevan M Shokat; L David Sibley
Journal:  J Med Chem       Date:  2013-03-26       Impact factor: 7.446

9.  Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells.

Authors:  Ana Zovko; Metka Novak; Petra Hååg; Dimitry Kovalerchick; Teresa Holmlund; Katarina Färnegårdh; Micha Ilan; Shmuel Carmeli; Rolf Lewensohn; Kristina Viktorsson
Journal:  Oncotarget       Date:  2016-08-02

10.  Identification of mutations in TgMAPK1 of Toxoplasma gondii conferring resistance to 1NM-PP1.

Authors:  Tatsuki Sugi; Kyousuke Kobayashi; Hitoshi Takemae; Haiyan Gong; Akiko Ishiwa; Fumi Murakoshi; Frances C Recuenco; Tatsuya Iwanaga; Taisuke Horimoto; Hiroomi Akashi; Kentaro Kato
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2013-05-18       Impact factor: 4.077

View more
  4 in total

1.  Identifying the Target of an Antiparasitic Compound in Toxoplasma Using Thermal Proteome Profiling.

Authors:  Alice L Herneisen; Saima M Sidik; Benedikt M Markus; David H Drewry; William J Zuercher; Sebastian Lourido
Journal:  ACS Chem Biol       Date:  2020-07-06       Impact factor: 5.100

2.  Alterations in Phosphorylation of Hepatocyte Ribosomal Protein S6 Control Plasmodium Liver Stage Infection.

Authors:  Elizabeth K K Glennon; Laura S Austin; Nadia Arang; Heather S Kain; Fred D Mast; Kamalakannan Vijayan; John D Aitchison; Stefan H I Kappe; Alexis Kaushansky
Journal:  Cell Rep       Date:  2019-03-19       Impact factor: 9.423

3.  Hydroxylamine and Carboxymethoxylamine Can Inhibit Toxoplasma gondii Growth through an Aspartate Aminotransferase-Independent Pathway.

Authors:  Jixu Li; Huanping Guo; Eloiza May Galon; Yang Gao; Seung-Hun Lee; Mingming Liu; Yongchang Li; Shengwei Ji; Honglin Jia; Xuenan Xuan
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  In vitro maturation of Toxoplasma gondii bradyzoites in human myotubes and their metabolomic characterization.

Authors:  Céline Christiansen; Deborah Maus; Ellen Hoppenz; Mateo Murillo-León; Tobias Hoffmann; Jana Scholz; Florian Melerowicz; Tobias Steinfeldt; Frank Seeber; Martin Blume
Journal:  Nat Commun       Date:  2022-03-04       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.